Flatiron Health has announced its active participation in the ISPOR 2025 Conference, scheduled from May 13-16 in Montreal, QC, Canada. ISPOR, or The Professional Society for Health Economics and Outcomes Research, is a prominent platform for showcasing advancements in healthcare research. This year, Flatiron's real-world data (RWD) will feature in over 15 research presentations, including eight posters authored by the company’s own scientists. These presentations highlight Flatiron's commitment to using innovative technologies like AI and machine learning to enhance the utility and application of RWD in oncology, particularly in regulatory and reimbursement decisions across international borders. One of the key highlights is a poster discussing the association between rash and survival in patients with advanced non-small cell lung cancer (NSCLC). Authored by Qianyu Yuan, Aaron Dolor, Yunzhi Qian, Doug Donnelly, Melissa Estevez, Yulia Kuznetsova, Nisha Singh, and Prakirthi Yerram, this research leverages machine learning to analyze patient data, providing valuable insights for clinical decision-making. Another notable presentation explores the use of regression discontinuity in time design to assess the effectiveness of pembrolizumab in the second-line treatment of advanced NSCLC. This study, co-authored by researchers from Flatiron Health, the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, and the University of Colorado School of Public Health, demonstrates how RWD can be applied to evaluate treatment outcomes in a robust and innovative manner. Flatiron will also present a deep learning-based natural language processing model for generating and validating real-world response data across multiple solid tumors. Kelly Magee, Qianyu Yuan, Auriane Blarre, Aaron Cohen, Aaron Dolor, Konstantin Krismer, Tori Williams, and Cherie Zhang will discuss the performance and reliability of this model, which has significant implications for improving the accuracy of RWD in clinical settings. In another presentation, Flatiron examines the role of RWD in recent drug approvals for multiple myeloma in the US and EU. Mamta Parikh, Peter McMahon, Susan Eng, Freda Boateng, Youssef Ghazi, Kerstin Schmidt, Michelle Brockman, and Mitch Sierecki explore how RWD can inform regulatory bodies and contribute to the approval process, emphasizing the global impact of their findings. Flatiron's research extends beyond Western contexts, with a focus on advancing breast cancer research in Japan using electronic health record (EHR)-derived RWD. Blythe Adamson, Dionne Ng, Harlan Pittel, Arun Sujenthiran, and Eri Tajima will share their work, highlighting the importance of culturally adapted research methodologies. Furthermore, a study on patient characteristics and treatment patterns in extensive-stage small cell lung cancer, co-authored by Wade Iams, Taavy Miller, Samantha Reiss, Navit Naveh, Badri Rengarajan, Amy Nguyen, Kristin J. Moore, and Xiaozhou Fan, will provide detailed insights into this aggressive form of cancer. The researchers are associated with Flatiron Health, Tennessee Oncology, and Jazz Pharmaceuticals, underscoring a collaborative approach to addressing complex oncological issues. A unique methodology for augmenting race and ethnicity in a real-world oncology cohort will be discussed by Gene Ho, Philani Mpofu, Olive Mbah, and Cleo Ryals. They use the Bayesian Improved Surname Geocoding method, which is crucial for ensuring that RWD accurately reflects patient demographics. Finally, Flatiron will present analytical approaches to estimate medication persistence from EHR data, focusing on tyrosine kinase inhibitors in patients with epidermal growth factor receptor (EGFR)-positive advanced NSCLC. Xinye Li, Brooke Jarrett, Brendan Kerr, Nate Wade, Patrick Ward, and Tony Proli will delve into the methods and implications of their study, offering practical tools for healthcare providers and researchers. During the conference, Flatiron Health will also participate in a panel discussion on the role of real-world evidence in precision medicine. The panel aims to explore how RWD can be effectively utilized across diverse healthcare systems to inform regulatory and reimbursement decisions. Visitors can engage further by scheduling meetings with Flatiron representatives, attending poster sessions, workshops, and panel discussions. Additional updates will be posted on Flatiron's social media platforms, including X and LinkedIn, where attendees can follow the hashtag #ISPORAnnual. Flatiron Health will be located at Booth #601. Flatiron Health, an independent affiliate of the Roche Group, is a leading healthtech company focused on transforming patient experiences and care through advanced data analytics and AI. Their mission is to leverage high-quality RWD to improve clinical outcomes and inform healthcare decisions, ultimately contributing to smarter, more personalized care for cancer patients worldwide. Industry insiders have praised Flatiron's innovative use of AI and machine learning in generating and validating RWD. These technologies not only enhance the scalability and reliability of real-world studies but also pave the way for more informed and precise medical practices. Flatiron's contributions to the field are seen as pivotal in bridging the gap between academic research and practical healthcare applications, making them a cornerstone of modern oncology data solutions.